Ncardia

Ho ho ho, the Ncardia team getting into the Christmas spirit! Happy holidays from the team and Santa! 🎅🎄

Final webinar of our series dedicated to neurodegenerative diseases! Sign up and learn how human iPSCs can be utilized to model disease-relevant signatures of Alzheimer's disease. In this 15-min webinar, our senior neuroscientist, Laura Calo, will present a model of tauopathy in hiPSC-derived cortical neurons and how to use it for drug discovery purposes.

Thursday February 17th | 3PM CET - 9AM ET

Sign up now and secure your spot!
http://ow.ly/epTv50HGkQM

Learn more about human iPSC technology and how it can benefit your drug discovery projects. Subscribe to our newsletter and keep up-to-date with our latest innovations, news and events.
Every 2 months you will receive information on the most relevant advancements and applications of human iPSCs in early drug discovery.

Subscribe now http://ow.ly/ixbB50HGjAv

Obtain robust and predictive conclusions about the safety and efficacy of your compounds with our integrated drug discovery solutions based on human iPSC technology.

✔️Custom solutions
✔️Flexible and accessible team
✔️Efficient ex*****on
✔️Processed results

> Explore http://ow.ly/Eeyx50HGgoL

Leveraging patient-specific background data in your preclinical research, using iPSC technology, will enable you to advance your cardiac drug discovery project more efficiently. Discover this and more advantages of using iPSC-based cardiac models in your drug discovery projects.

Learn more: http://ow.ly/xBwI50HBqCc

Assess electrophysiology, contractility and cardiac Troponin I release of human iPSC-cardiomyocytes with our multiparametric functional and structural cardiac safety analysis.

- Acute and long term analysis
- Reproducible results
- Clinically relevant

Learn more http://ow.ly/EuMq50HzB1b

We had a fantastic webinar session last week! Thanks to all the attendees for coming and promoting interesting discussions with our scientists Calo and Onofre.
In case you missed it, here is the replay
http://ow.ly/Avpb50Hzzjk

Webinar: Robust hiPSC-derived neuronal and glial in vitro drug discovery assays In this webinar, learn about the benefits and challenges of hiPSC-derived neuronal and glial cells and optimized assays to model neurodegeneration

Last spots available! Gain insights into how human iPSC-derived neuronal and glial cells can model especific phenotypes associated with neurodegeneration.

Sign up now👉http://ow.ly/Tac750HvPMH

Obtain translational results of the safety and efficacy of cardioactive compounds using human iPSC-derived cardiomyocytes and our contractility analysis solutions.

This is a physiologically relevant assay available for iPSC-based cardiac in vitro models that mimics tissue elasticity in multi-well format and provides you with reproducible information.

Learn more 👉http://ow.ly/T6qx50HvOYZ

Learn the benefits that human iPSC-derived cardiomyocytes bring to cardiac disease modeling and drug discovery. In this article, Kosmidis, senior scientist at Ncardia, discusses the key issues hampering the development of new therapies for cardiac diseases and explains the need to incorporate more physiologically relevant disease models in drug discovery.

👉http://ow.ly/2hqn50HvKbi

Learn how to develop and optimize robust assays with human iPSC-derived neuronal cell types to recapitulate disease-specific phenotypes.
Join us for the live session with Q&A next Thursday 20th at 3PM

https://event.webinarjam.com/register/15/8q4r3av

Developing and performing predictive assays to recapitulate disease phenotypes in high-throughput can be challenging. Explore our assay development solutions to find out how Ncardia can make this process easier for you.

✔️+ 10 years of experience with hiPSCs
✔️Clinically relevant readouts
✔️Miniaturized assays for high-throughput screenings

http://ow.ly/gWTw50Hpnwf

Learn how iPSC-based disease models can help you make better predictions in the early stages of drug discovery. Models from patient-derived cells, combined with the right assays, will make a big difference in your screening campaigns.

Discover more in our latest publication in IBI journal, Volume 4, Issue 4, pages 26-29

http://ow.ly/TwL150Hpl7x

Gain detailed understanding of compound effects on vascular barrier function through our Endothelial Barrier Toxicity Service. Learn how this assay monitores changes in electrical impedance across the hiPSC-derived endothelial cell monolayer. The assay includes high-content, real-time and label-free impedance-based technology.

Learn more
http://ow.ly/rZlv50HcUz1

Cell viability and health: Endothelial Barrier Toxicity A toxicity assessment of drug induced vascular leakage, measuring electrical impedance across the endothelial barrier.

Read this interview with our CEO Stefan Braam in Leidsch Dagblad, a Dutch local newspaper. He explains the Ncardia's plans for growth after receiving 60M$ investment. "The future opportunities for iPSCs are enormous. We are expanding and so do our team and technologies."

If you want to join our team visit our careers page
👉 http://ow.ly/WxqE50HmEnT

Ncardia kweekt stamcellen om medicijnen uit te testen | De Koers van het Bio Science Park Zestig miljoen dollar, dat is de investering die het Leidse biotechbedrijf Ncardia vorige maand ophaalde om zijn stamceltechnologieproductie op te schroeve...

✨Happy new year from the Ncardia Team! We wish you a wonderful 2022 full of discoveries. Stay connected because we have great plans for 2022

Great memories from 2021! 😀 #4 We have formed a strategic partnership with Kiniciti to build GMP capabilities to support iPSC cell therapy platforms and human cell-based in vitro discovery services.

With this partnership, we can enhance our technology platforms to strengthen our offerings.

Don't miss what is coming in 2022!
http://ow.ly/jSgI50Hfi7F

Great memories from 2021! 😀 #3 In November, our directors of manufacturing and discovery technology discussed the advantages, challenges and solutions of implementing hiPSC-technology into drug discovery and development. You can still watch the webinar on demand!

Watch now:
👉http://ow.ly/iR3h50Hfhuc

Great memories from 2021! 😀 #2 Learn how we generated a model of Parkinson's disease using our human iPSC-derived neuronal cell types to enable assessment of alpha-synuclein pre-formed fibril-induced toxicity and phenotype rescue assays.

Download now
http://ow.ly/BKh950HfieV

Great memories from 2021!😀 #1 We started the year sharing this white paper. Learn how to automate cell culture and high-throughtput compound screening on the Fluent Automation Workstation.
This white paper describes the automated identification of cardiac hypertrophy modulators using a human iPSC-derived cardiomyocyte disease model

Download now
http://ow.ly/yVOo50HfcpI

Whitepaper Automated large-scale manufacturing and high throughput screening of hiPSC derived cardiomyocyte disease model

Angiogenesis, the sprouting of new blood vessels, has been identified as an important target for treatment of a variety of diseases. Using our state-of-the-art assay, our experts can help you assess the effect of your compounds on blood vessel formation: http://ow.ly/CrqJ50Dc1IX

Disturbances in intracellular calcium levels can play a role in many neurodegenerative and cardiac diseases, making calcium signaling assays important tools in drug discovery. With our calcium signaling service, we offer you a range of technologies to help you assess cardiac and neuronal calcium signaling in health and disease: http://ow.ly/fhIb50DoM3H

Effective drug discovery greatly relies on the availability of predictive pre-clinical models. At Ncardia, we combine our broad iPSC expertise with manufacturing experience for a variety of cell types, to provide you with assay results with a high clinical relevance, tailored to your project needs. Discover our range of assay services: https://ncardia.com/assay/?utm_source=facebook&utm_campaign=recognition-social_drugdiscovery&utm_medium=social